Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

NCT05503797 is registered in ClinicalTrials.gov with Fore Biotherapeutics as lead sponsor.

NCT NCT05503797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05503797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
Lead sponsor
Fore Biotherapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
February 21, 2023
Completion date
December 28, 2028
Enrollment
254 (estimated)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

cancer harboring braf alterations, hgg, lgg, solid tumors